US 12,467,039 B2
Kaurenoic acid 13-hydroxylase (KAH) variants and uses thereof
Andrew P. Klein, Emeryville, CA (US); Sean Lund, Emeryville, CA (US); Gale Wichmann, Emeryville, CA (US); Irina Koryakina, Emeryville, CA (US); Kyle Hogan, Emeryville, CA (US); and Svetlana Borisova, Emeryville, CA (US)
Assigned to Amyris, Inc., Emeryville, CA (US)
Appl. No. 17/608,437
Filed by Amyris, Inc., Emeryville, CA (US)
PCT Filed May 1, 2020, PCT No. PCT/US2020/031171
§ 371(c)(1), (2) Date Nov. 2, 2021,
PCT Pub. No. WO2020/227148, PCT Pub. Date Nov. 12, 2020.
Claims priority of provisional application 62/842,810, filed on May 3, 2019.
Prior Publication US 2022/0282228 A1, Sep. 8, 2022
Int. Cl. C12N 9/02 (2006.01); C12P 19/56 (2006.01)
CPC C12N 9/0073 (2013.01) [C12P 19/56 (2013.01)] 17 Claims
OG exemplary drawing
 
1. A kaurenoic acid hydroxylase variant comprising the amino acid sequence of SEQ ID NO:1, further comprising one or more amino acid substitutions selected from the group consisting of: W8G, L11V, W29A, W29C, W29T, W29V, V30F, N49A, N49R, F53R, L54G, Y55G, Y55P, Y55S, G56D, G56N, G56S, D57G, M58G, M58P, E60G, E60R, N61P, S62R, L64D, L64G, L64N, L65G, L65S, A68G, A68I, A68P, K69G, K69P, S70P, P72C, P72D, P72G, P72T, M73G, M73H, Q84C, Q84L, F88D, F88R, F88S, F88V, D102Y, I104A, I104D, 1104H, I104N, I104R, K119S, K119V, K119Y, T123D, I129R, 1132G, S133G, S133R, N160D, N160T, P161C, P161D, T162A, T162G, H164G, S165D, S165P, K167G, K167H, K167S, M171F, W202A, W202C, W202Q, W202V, L205I, E206D, N207F, A210G, T216A, T216G, A217L, A217V, T220E, T220R, K224C, K224I, K224V, F229Y, E230C, E230G, L232M, L232Y, R233C, R233T, A236R, I237C, Y238C, T240D, A242D, A242G, Q244D, Q244G, S245G, F246G, F246S, M258G, K267D, I284G, K291C, K291S, D292P, D293C, A297F, A297V, A297Y, L303D, K314P, C327I, F332L, Q335V, S339A, S339G, V340A, V340S, V343G, T378D, H379G, A396F, T403V, S452D, R458D, S460I, G466D, G466F, G466S, N475D, N475G, L485F, H491P, A503C, S505R, Y506V, R507A, R507E, R507G, I508L, T509V, Q513G, and Q513R.